Form 4: Arcutis Biotherapeutics Executive Sells Shares to Cover Tax Obligations

Patrick Burnett, Senior Vice President and Chief Medical Officer of Arcutis Biotherapeutics, sold 4,782 shares of common stock on March 4, 2024, to satisfy tax withholding obligations related to vesting Restricted Stock Units.

Summary

• On March 4, 2024, Patrick Burnett, Senior Vice President and Chief Medical Officer of Arcutis Biotherapeutics, sold 4,782 shares of the company's common stock.
• The sale was executed at a weighted average price of $11.1212 per share.
• The transaction was conducted to cover tax withholding obligations associated with the vesting of Restricted Stock Units.
• Following the sale, Burnett directly owns 269,300 shares of Arcutis Biotherapeutics.
• The sale was executed pursuant to a pre-arranged Rule 10b5-1 trading plan.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction to cover tax obligations, and the use of a 10b5-1 plan suggests it was pre-planned.

Industry Context

Insider sales are a common occurrence, especially to cover tax obligations related to equity compensation. The use of a 10b5-1 trading plan suggests the sale was pre-planned and not based on current market information.

Stakeholder Impact

• The sale is unlikely to have a significant impact on shareholders, as it is a relatively small transaction by an executive to cover tax obligations.

Key Dates